Table 2.
Sample Patient Profiles from the IEEG Portal.
Patient ID | I002_P002 | Mayo Clinic Study 005 | I002_P005 | I002_P006 |
---|---|---|---|---|
Institution | Hospital of the University of Pennsylvania | Mayo Clinic | Hospital of the University of Pennsylvania | Hospital of the University of Pennsylvania |
Epilepsy Type | Localization-related; Left frontal onset, left cortical dysplasia | Bi-Temporal Onset | Localization- related; Left temporal onset (secondary to hemorrhagic HSV encephalitis) | Localization-related; Symptomatic meningitis |
Engel Outcome | 1 | 1 | 4 | 1 |
Seizure Type | Simple partial and generalized tonic- clonic of left temporal onset | Focal Complex partial-endpoint of seizure- not evolving to secondary generalized | Complex partial seizures of left temporal onset and status epilepticus | Complex partial seizures of right temporal onset with secondarily generalized tonic-clonic seizure |
# of Seizures | 1 | 0 | 5 | |
Age during First Seizure | 4 | 21 | 30 | 11 |
Age at Admission | 20 | 26 | 35 | 32 |
Sample Past Anti-Epileptic Medications | carbamazepine, topiramate, levetiracetam, clobazam, valproic acid | - | phenytoin, valproic acid, levetiracetam | carbamazepine, zonisamide |
Imaging available | T1 MPRAGE, T2 FLAIR, Post-Implant T1 MPRAGE and FLAIR, Post-Implant CT, 6 months post- op T1, T2, FLAIR, DWI | MRI T1 pre- implant, SPECT ictal/interictal, MRI T1 post implant, CT post implant | Pre-Implant T1 MPRAGE and T2, Post-Implant T1 MPRAGE and FLAIR, Post-Implant Head CT | T1 MPRAGE, T2 FLAIR, T2 Susceptibility-Weighted, DTI, Pre-Implant T1 MPRAGE and T2 FLAIR, Post-Implant T1 MPRAGE and FLAIR, Post-Implant CT, 6 months post-op T1, T2, FLAIR |
Four patients and their profiles on the IEEG Portal. Dates of hospital admission for epilepsy monitoring have been standardized to start on Jan-01-2000. All other dates have been adjusted accordingly. Note that some data is not available and marked by -. All patients who have lesional epilepsy will have lesion findings noted under MRI report summaries in the respective patients’ clinical reports. All lesional patients will have appropriate pathology and imaging findings reported, whether lesions are malformations of cortical development, vascular, or low-grade glial tumors.